Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will have discussions with NICE on the potential merits of prescribing Androfeme for the menopause.

The Department has no plans to discuss Androfeme with the National Institute for Health and Care Excellence (NICE) and has made no assessment of the potential merits of prescribing Androfeme. Androfeme does not have a marketing authorisation for use in the United Kingdom.

Newly licensed medicines are appraised by the NICE, which is the independent body responsible for developing evidence-based guidance for the National Health Service on new medicines that represent a clinically and cost-effective use of resources. If Androfeme is granted a marketing authorisation in the future for this indication, the NICE will consider producing guidance under the appropriate programme, such as its technology appraisal programme.